Osphos Injection is a bisphosphonate solution for the control of clinical signs associated with navicular syndrome in horses four years and older. Osphos Injection inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts. OSPHOS is supplied as 15 mL (900 mg) of clodronate disodium (60 mg/mL) per vial and is ready-to-use (no reconstitution or dilution required).
Features of Osphos:
- Prevents bone resorption because it exerts direct effects on the cells of osteoclasts and binds to calcium phosphate crystals, which inhibits their dissolution and formation
- Excellent option for horses proven through radiography to have bony changes caused by navicular syndrome
- Injectable solution of bisphosphonate that aids in the control of the clinical signs of navicular syndrome
- The only option injected intramuscularly
- Contains 60mg clodronate in each mL
Field studies have shown that the most frequently-reported adverse reactions, which occurred within 2 hours of treatment, were:
- Colic
- Pawing
- Cramping
- Nervousness
- Discomfort
After hand walking for 10-15 minutes, 8 out of the 10 horses with the symptoms listed above experience clinical sign resolution. One horse experienced resolution without any hand walking. Just one underwent treatment for colic. That particular horse also experienced hives, recovering following dexamethasone and flunixin treatment.
Osphos Injection is administered at 1.8 mg/kg by intramuscular injection up to a maximum dose of 900 mg per horse (one vial). Divide the total volume evenly into three separate injection sites. Discard unused vial contents. OSPHOS is provided in a single use vial and does not contain a preservative.
If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs rec
http://horsemedonline.com/
Reviews
There are no reviews yet.